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Abstract
Background: Successful dissemination of the new classification of periodontitis is
facilitated by emphasis on the basic ground rules, clarification of ambiguities, and
identification of “gray zones” where thoughtful application of the guidelines by an
informed, experienced clinician is paramount to arrive at a correct Stage and Grade.
Methods: Highlighted ground rules are (1) Stage is a patient-based, not a tooth-based
concept, therefore, a single Stage is assigned per patient; (2) Stage can shift upward
over time, if the periodontal status deteriorates, but the initially assigned Stage is
retained even after improvement post-therapy; (3) the complexity factors that deter-
mine Stage must be evaluated collectively, not in isolation, to arrive at a clinically
meaningful assessment; (4) a single Grade is assigned to a patient based on a delib-
erate evaluation of the “biological fabric” of the case, in terms of history of/risk for
further progression, interplay of risk factors, and the two-way effects of periodontitis
or its treatment on general health; (v) shift of Grade over time is possible towards
either direction, after thorough, collective, evaluation of changes in the above param-
eters. Exemplified gray zones include a radiographically intact patient with minimal
attachment loss in older age; presence of “frank” periodontitis affecting a single tooth;
and assessment of factors that do/do not lead to increased complexity of therapy.
Conclusion: Differentiating between Stage I/II versus Stage III/IV periodontitis is
relatively uncomplicated; further distinction between Stages and correct assignment
of Grade requires nuanced, thorough interpretation of a broad array of findings by a
knowledgeable clinician.
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1 INTRODUCTION
A new classification of periodontal diseases and conditions
was introduced in 2018,1,2 following the deliberations and
the consensus reports of an International Workshop that took
place in November 2017. In the time since then, educational
institutions and the periodontal community have begun to uti-
lize the new classification according to the stipulated prin-
ciples, and a number of dissemination efforts to the larger
dental community, allied health professionals, patients and
other constituencies are underway. As is the case with
all new systems that re-classify disease modalities into
novel schemes, successful implementation involves a learn-
ing curve, and additional interpretations of both the “letter”
and the “spirit” of the guidelines are inevitably necessary.
To facilitate this process, the Editors of the Journal of Peri-
odontology decided to initiate a series of short, authoritative
commentaries to address specific items in the position paper
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and the consensus report of Workgroup 23 that admittedly
benefit from further clarification. In this first report, we re-
iterate some basic principles, emphasize important “ground
rules,” identify potential gray zones, and provide practical tips
that will help clinicians to seamlessly navigate the new system
in their everyday clinical practice. Subsequent commentaries
will further dwell on specific topics that will be exemplified
by means of clinical case reports.
2 PATH TO THE NEW
CLASSIFICATION
One of the major learnings over the past twenty years has
been the realization that multiple risk factors, including envi-
ronmental exposures and genetic predispositions may com-
bine in different patients to modify an individual’s phenotypic
response to the bacterial challenge and/or their response to
periodontal therapy. In addition, we know from clinical expe-
rience and research evidence that the majority of periodonti-
tis cases respond predictably to mechanical biofilm disruption
and subsequent plaque control; and that further disease pro-
gression despite standard periodontal treatment will generally
occur in a small subset of patients. We also know that while
average levels of attachment loss at different ages are gener-
ally consistent throughout the world, there are individuals in
each age group who have experienced a level of disease sever-
ity that is disproportionate to that expressed by the majority
of their peers.4
These learnings and clinical observations indicated that
there was a need for additional information beyond the cur-
rent level of severity to more specifically characterize a
patient’s type of periodontitis. Moreover, these clinically
observable exceptions in periodontitis expression and the clin-
ical response to standard principles of therapy necessitated
an evolvement in the classification of periodontal diseases
that we have used so far. Important questions that arose and
challenged older paradigms were (1) whether the clinically
observed distinct disease phenotypes are truly different dis-
eases or, rather, variations of a common disease entity; (2)
whether these phenotypes were indeed the result of different
infections by specific bacteria or bacterial complexes that had
been earlier implicated as causative factors; and (3) the exact
role of multiple risk factors.
3 KEY CONCEPTS AND GROUND
RULES OF THE NEW
CLASSIFICATION OF
PERIODONTAL DISEASES
The new classification system is quite different from
the one used for almost two decades, because, with the
exception of specific forms (necrotizing periodontal diseases
and periodontitis as a manifestation of systemic disease),5,6
periodontitis is recognized as a single nosological entity that
is further classified using a two-vector system (Stage and
Grade).1 Stage reflects the severity of the disease (expressed
through attachment loss and bone loss), but also tooth loss
that has occurred as a result of periodontitis, at least as well
as can be determined. In addition, it reflects anticipated com-
plexity of treatment required to eradicate/reduce the current
level of infection and inflammation, and to restore patient
masticatory function. Grade describes additional biological
dimensions of the disease including the observed or inferred
progression rate, the risk for further deterioration due to envi-
ronmental exposures (such as smoking) and co-morbidities
(such as diabetes), and the risk that the disease or its treat-
ment may adversely affect the particular patient’s general
health status. Bleeding on probing (BOP) is a valuable clin-
ical parameter to help assess current levels of inflammation
and residual risk post-treatment, but BOP does not influence
the classification.1
We assume that the reader of this commentary is familiar
with the detailed criteria described in the tables that outline
the Stage and Grade criteria of the classification, so here we
will briefly go through key steps of the process to be followed
when implementing the new knowledge in the everyday clin-
ical practice.
3.1 Assessment of stage
The first step is to define if the patient has periodontitis;
this is ideally performed by assessing presence of clinical
attachment loss but, importantly, this determination involves
clinical judgement: If (1) interproximal attachment loss is
present at least at two different, non-adjacent teeth, and (2)
the observed attachment loss cannot be attributed to traumatic
factors or non-periodontitis related etiologies (e.g., root frac-
ture, endodontic infection, surgical trauma), then the patient
has periodontitis. In the absence of interproximal attachment
loss, but if attachment loss that cannot be ascribed to non-
periodontitis-related causes is present at buccal or lingual
surfaces, a diagnosis of periodontitis requires concomitant
presence of clinical attachment loss of ≥3 mm and prob-
ing depth of ≥3 mm at ≥2 teeth. Clinicians will frequently
confirm the presence of attachment loss by corresponding
interproximal alveolar bone loss on radiographs. It must be
remembered, however, that tissue loss needs to encompass a
substantial portion of the buccal-lingual dimension before it
can be visualized by conventional radiographs. Thus, absence
of readily discernible bone loss does not preclude presence
of frank periodontitis of incipient severity. This is exactly the
reason why the diagnosis of periodontitis is based on attach-
ment loss rather than bone loss which is admittedly more
widely assessed; use of bone loss as the primary criterion
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would result in significant under-detection of incipient peri-
odontitis and an increase in “false negatives.”7
After ascertaining that the patient has periodontitis, the
clinician should proceed with an assessment of Stage. A key
element of the new classification, supported by our current
knowledge, is that Stage I and Stage II adult patients are likely
very different from Stage III and Stage IV patients in terms of
how the host copes with and responds to the bacterial chal-
lenge. Stage I and II patients show periodontitis of incipient
or moderate severity, have not lost any teeth because of the dis-
ease, and are likely to respond predictably to standard therapy
based on the principles of sustainable reduction of the bacte-
rial burden. In contrast, in Stage III and Stage IV periodontitis
patients, it is most likely that one or several intrinsic or envi-
ronmental risk factors adversely affect the ability of the host
to respond to the bacterial infection and to contain the tissue
damage; thus, these patients seem to be on a different “dis-
ease trajectory” than patients of the same age with Stage I or
Stage II periodontitis. Thus, Stage III and IV represent more
complex cases that require more specific knowledge, broader
training and more clinical experience to manage successfully.
Based on the above, the initial staging of a case should
involve a focused, high-level assessment of the patient’s med-
ical history, radiographs, and probing chart to distinguish
between Stage I or II versus Stage III or IV periodontitis, using
two key discriminatory variables that can distinguish between
the two aggregate groups, that is, the severity of tissue damage
and the presence of periodontitis-associated tooth loss.
This high-level assessment (Figure 1A) uses a narrow
set of parameters and provides a starting point for a more
detailed assessment. Since the majority of adult patients in
non-specialty dental offices will likely be Stage I or II, many
patients can be staged by focusing on the limited parameters
highlighted in Figure 1B. If the high-level assessment indi-
cates the patient is more likely to be a Stage III or IV, the
clinician will need to evaluate the more complex parameters
highlighted in Figure 1C.
In this step, the clinician needs to study in detail the avail-
able full-mouth periodontal charting and full-mouth series of
intra-oral radiographs. The distinction between Stage I and
II periodontitis will be primarily carried out by evaluating
severity of bone loss at areas of the dentition with the most
advanced destruction.
A frequently raised issue is how to reliably differentiate
between bone loss of up to 15% of the root length versus
bone loss extending between 15% and 33% of the root length.
Clearly, the point here is not to scrutinize the level of bone
loss with a level of precision extending to single percentage
points. Instead, the intent is to distinguish between an incip-
ient stage of periodontitis that has barely resulted in alveolar
bone loss, from more substantial bone loss that extends within
the coronal third of the root length. Clearly discernible inter-
proximal bone loss within the coronal third of the root length
will, in most situations, be commensurate with Stage II rather
Stage I disease. In contrast, Stage I disease is usually charac-
terized by incipient attachment loss in the presence of early
radiographic evidence of disruption in the alveolar bone sup-
port (e.g., a break in the integrity of the lamina dura) rather
than pronounced increase in the CEJ-bone crest distance.
If the preliminary assessment is that the patient suffers
from either Stage III or Stage IV periodontitis, the distinction
between these two stages will be based either on the amount
of tooth loss that can be attributed to periodontitis (one to four
teeth versus five or more teeth lost) or on the presence of the
various complexity factors listed in Figure 1 that need to be
appreciated in detail. It must be realized that either Stage III
or Stage IV disease may reflect severe or very severe peri-
odontitis. However, the primary distinction between the two
requires that an experienced clinician ponders the following
two central questions that essentially represent a distillation of
the case’s treatment: (1) does the patient’s extent and severity
of periodontitis constitute a threat for the survival of individ-
ual teeth or rather of the survival of the entire dentition? and
(2) does the total therapy envisioned to address the sequalae
of periodontitis in the particular patient involve extensive,
multi-disciplinary oral rehabilitation? If the assessment is that
the current level of periodontitis threatens the entire denti-
tion and, consequently, treatment requires extensive oral reha-
bilitation involving collaboration of multiple experts (beyond
the need for occasional extractions and a limited prosthetic
reconstruction), then the appropriate Stage for the patient is
IV rather than III. Importantly, this assessment involves a col-
lective assessment of the potential complexity factors, rather
than a mere “checking of a box” approach of isolated features.
It should be emphasized that Stage is a patient-based
attribute, not a tooth-based assessment; consequently, a
F I G U R E 1 Figure subparts A, B, and C, staging a periodontitis patient, were reproduced with permission from the Journal of Periodontology,
Tonetti et al.1 (A) The vertical red line boundary was added to the Staging table to emphasize the distinctions between Stages I and II versus Stages
III and IV and to guide the focus of a clinician’s thought process with assessment of each patient. (B) Shows selected periapical radiographs that
capture one patient’s overall general radiographic bone loss, which is in the coronal third of the root length. The orange box in the figure defines
characteristics of Stages I and II, which include the most likely severity of periodontitis for this patient. This initial high-level disease assessment
guides clinicians to target Stages I and II based on clinical and radiographic bone loss of patients. (C) Shows selected periapical radiographs that
capture one patient’s overall general radiographic bone loss, which is in the middle third or beyond of the root length. The orange box in the figure
defines characteristics of Stages III and IV, which include the most likely severity of periodontitis for this patient. This initial high-level disease
assessment guides clinicians to target the parameters listed for Stages III and IV based on clinical and radiographic bone loss of patients
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Table is reproduced1 by permission of the Journal of Periodontology. Note that Grade B should be assumed for each patient unless evidence exists for a more rapid rate
of progression (Grade C) or a slower rate of progression (Grade A) than expected.
single Stage is ascribed to an individual patient at a given time.
Although the most severely affected segments of the denti-
tion are the ones that inevitably define the patient’s Stage, the
clinician is encouraged to expand the description with addi-
tional pertinent information. The terms “localized” or “gen-
eralized” will be used to describe the extent of the denti-
tion that is affected by the Stage-defining severity. In addi-
tion, a patient with, for example, localized Stage III periodon-
titis, may frequently include segments of the dentition with
mild or moderate severity of attachment/bone loss; this fact
should be acknowledged in the “narrative” portion of the case
description.
Another frequently raised question is whether a patient’s
Stage can change over time. If a patient that has been staged
at a given time point experiences significant disease pro-
gression or disease recurrence after therapy that results in
increased severity and/or more complex treatment needs, then
stage must be shifted upwards at the time of the subse-
quent examination, as appropriate. However, although the
severity of attachment loss and/or bone loss can be reduced
substantially from beyond the coronal third to within the coro-
nal third in cases of successful regeneration therapy, it is
advised that the patient retains the Stage originally assigned
prior to the treatment.
3.2 Assessment of grade
Evidence over recent decades supported that the majority of
periodontitis patients are on a trajectory that will result in
predictable clinical responses if standard principles of plaque
control are applied diligently to the prevention and treatment
of periodontitis (Table 1). However, according to current esti-
mates, ≈20% to 25% of our patients are on a different tra-
jectory and, therefore, are less likely to respond predictably
to standard approaches to managing periodontitis.8 The pri-
mary goal of grading is to determine which of two disease
paths a specific patient is traveling on, and use this infor-
mation to guide the most appropriate treatment strategy that
will lead to successful outcomes. Of course, there are no facts
about the future, only probabilities, therefore, our classifica-
tion of individual patients includes grading to help generate
our best estimate at the time as to the patient’s likely path.
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We assume a moderate periodontitis progression rate (Grade
B) until clinical or medical history provides evidence of more
rapid progression or risk factors that increase the probabil-
ity of more rapid progression (Grade C). In some cases,
radiographic evidence suggests a slower progression rate than
one might expect given the case history and patient’s age
(Grade A). We anticipate that planned reviews of evidence
supporting modifications to staging and grading classifica-
tions will refine boundaries for defining Grades A, B, C.
4 THE BASIS FOR GRADING A
PATIENT
Grading is based on three fundamental principles: (1) Not all
individuals are equally susceptible to periodontitis,4,9,10 (2)
Periodontitis progression and severity is a function of multi-
factorial influences on a patient’s response to the microbial
challenge. Multiple factors often interact to influence clini-
cal phenotypes,8,11,12 and (3) Some periodontitis cases require
more intensive control of the microbial biofilm and inflamma-
tion than achieved using current principles of care.13
Consequently, there are three primary goals for Grading a
patient with periodontitis:
1. To assist in stratifying each patient in terms of which of
two general paths best capture the patient’s periodontitis
trajectory. A “Path 1” patient has minimal likelihood of
disease progression, and clinical treatment responses are
expected to be predictable after applying standard prin-
ciples of periodontitis treatment based on biofilm disrup-
tion and regular plaque control; in contrast, in a “Path 2”
patient, there is an increased likelihood of disease progres-
sion and less predictable clinical response to standard peri-
odontitis prevention and treatment principles.
2. To assist new protocol development for management of
periodontitis cases that are less likely to respond to current
principles for periodontitis prevention and treatment.
3. To assist in development of additional approaches to man-
agement of certain periodontitis cases that may favorably
influence systemic health.
Factors to be assessed to determine the patient’s grade
include the actual or inferred rate of periodontitis progression,
presence, and control of risk factors, and status of systemic
inflammation.
4.1 Progression
The most reliable indication of disease progression or stability
is captured by longitudinal assessments of radiographic bone
loss (RBL) or CAL. For most patients progression rate must
be inferred using the most severe RBL observed in relation to
patient age (% bone loss/age ratio).
F I G U R E 2 Estimate radiographic bone loss at site that appears
to have most severe destruction and determine whether the bone loss is
likely to be in the most coronal third, the middle third, or the most
apical third of the root length. Site a bone loss extends well into the
middle third of the root length, whereas site b bone loss appears to be
within the coronal third of the root length
T A B L E 2 Calculating the ratio of radiographic bone loss at most
severe sites divided by age in years






30% 50 30/50 = 0.60
40% 50 40/50 = 0.80
50% 50 50/50 = 1.00
60% 50 60/50 = 1.20
Bone loss assessment as a percentage of root length is
inherently a rough estimate based on the clinician’s interpre-
tation of the most apical location of alveolar bone support,
location of the CEJ, and location of the root apex. The exam-
ple below (Figure 2) shows bone loss of ≈60% or greater
of root length. In a 50-year-old patient, this would represent
a >1.0 bone loss/age ratio, as shown in Table 2. A maxi-
mum bone loss ratio by age >1.0 will classify the patient
as Grade C based on progression rate. Given the limited
precision of assessments used to calculate the ratio of great-
est RBL by age, clinicians should use clinical judgement for
ratios close to 1.0.
4.2 Risk factors
The multifactorial nature of periodontitis is based on
evidence that multiple factors may contribute to an individ-
ual’s susceptibility to develop disease and often to respon-
siveness to specific types of therapy. The Grading table lists
the two most well-documented risk factors for periodonti-
tis, namely smoking14,15 and diabetes mellitus.16,17 In gen-
eral, clinicians should consider a patient’s other systemic
factors that may influence progression of periodontitis and
treatment responses. These may include obesity, chronic
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inflammatory diseases such as rheumatoid arthritis, chronic
depression, genetic factors, and other factors from a compre-
hensive medical history.11,18–20
The goal for the clinician is to identify patients more likely
to exhibit progression of periodontitis and to require intensive
monitoring, intervention, and physician collaborations to
help control systemic factors that may complicate host
modulation of the chronic inflammatory component of severe
periodontitis.
Patients classified as initial (Stage I) or moderate
(Stage II) periodontitis will not routinely have sufficient peri-
odontitis progression to qualify as a Grade C patient, unless
they are very young, and therefore, may have a bone loss/age
ratio of>1. However, some Stage I or II patients may be heavy
smokers or have poorly controlled Type II diabetes and may
therefore, qualify for a Grade C diagnosis through their risk
profile. The exposures that account for Grade C should be tar-
gets for behavioral modification (i.e., smoking cessation) or
additional therapeutic intervention in collaboration with the
patients’ physician to better achieve metabolic control in dia-
betes, as they entail greater risk for less predictable clinical
outcomes using standard principles of disease management.
In Stage III and IV patients, assessment of Grade may often
be defined indirectly by the apparent rapid bone loss relative
to the patient’s age; however, Grade modifiers, beyond being
informative of the risk of further progression and likelihood
of successful treatment outcome are obvious interventional
targets.
4.3 Systemic impact risk
Substantial evidence from large clinical databases involv-
ing >150,000 patients with a chronic inflammatory disease
compared with >370,000 controls indicate that the pres-
ence of certain chronic inflammatory diseases influences
the likelihood of a second chronic disease to be concomi-
tantly manifested.21–23 Although there is substantial evidence
associating periodontitis with other diseases such as cardio-
vascular disease, Type II diabetes, and adverse pregnancy out-
comes, evidence that treatment of periodontitis will result in
predictable benefits with respect to any of those systemic con-
ditions is rather limited.24 The systemic inflammatory bur-
den of periodontitis is well-documented, at least as measured
by high sensitivity C-reactive protein (hsCRP).25,26 Given the
well documented role of elevated hsCRP in cardiovascular
diseases,27–29 as well as in other inflammatory conditions, the
impact of periodontal treatment on plasma hsCRP levels may
be an important parameter to monitor in certain patients with
Stage III or IV periodontitis.
4.4 Biomarkers
Current evidence indicates that certain combinations of sali-
vary biomarkers may add value in the assessment of periodon-
tal therapy relative to stability of the case post-treatment.30,31
It is expected that additional evidence of clinical utility and
further advances with novel biomarkers may better inform
objective assessments of Grade.
A common question is whether Grade can change over
time. An upwards revision of Grade is possible if the % bone
loss/age ratio increases substantially, or the risk profile of
the patient deteriorates. Conversely, downgrading is also
possible, if the determinants of Grade when it was originally
assigned are no longer prevalent. The clinician is urged to
carry out such modifications judiciously and after thorough
consideration of the risk factors at play as well as of the
consequences of the altered Grade on the patient’s overall
management plan.
5 INTERPRETATIONAL
CHALLENGES AND “GRAY ZONES”
In a time of evidence-based healthcare and comparative
effectiveness research, some clinicians would like a simple
algorithm to convert a patient’s clinical findings to a stage
and grade that is a robust periodontitis classification. It has
become evident in medicine that in spite of extensive evidence
to guide certain clinical decisions, new technologies and more
evidence often expands “gray zones” which do not have sim-
ple decision guidelines.32 We recognize that knowledge and
clinical judgement will be required for classification of some
patients. Below, we provide narrative examples of commonly
encountered diagnostic “gray zones” and offer suggestions of
how they can be addressed.
1. A male 65-year-old patient has experienced no tooth loss,
is radiographically intact, has no interproximal pockets
with a depth >3 mm. The level of the gingival margin (GM)
interproximally is, at most sites, coronal to the CEJ, except
for a few surfaces located at non-adjacent teeth where the
GM is located at the CEJ. A loss of attachment of 2 mm
is recorded at these few surfaces. Does this patient have
periodontitis?
This is a borderline case. According to the above descrip-
tion, the probe tip apparently penetrates within the junctional
epithelium to a level apical to the CEJ at a few interprox-
imal sites with shallow probing depth, no visible recession
and no radiographic evidence of alveolar bone loss. Since this
middle-aged patient appears to be periodontally intact, a diag-
nosis of “periodontitis” is not justified. It must be empha-
sized, however, that the same phenotype in a much younger
patient may signify “true” incipient periodontitis. Again, clin-
ical judgement is paramount at arriving at a correct diagnosis
after assessing the totality of the patient data.
2. The severity of periodontitis in a 50-year old patient, based
on RBL at the sites of the most advanced destruction,
KORNMAN AND PAPAPANOU 359
is compatible with Stage II disease (e.g., the bone loss
extends within the coronal third of the root). Does pres-
ence of one or a few 6 mm pockets necessarily upshift the
diagnosis to Stage III?
Not necessarily. If the severity of bone loss does not extend
beyond the coronal third of the root length, presence of a cou-
ple of 6 mm pockets does not automatically entail a need for
more complex treatment. Upstaging because of “complexity
factors” requires a meaningful, integrated appraisal of these
factors by an experienced clinician. Correct implementation
of the Staging system does not lend itself to automated algo-
rithms based on checkboxes or presence/absence of isolated
features.
3. According to the new classification, a diagnosis of peri-
odontitis requires a minimum of “at least two teeth”
affected by interproximal attachment loss. Does this mean
that a patient that presents with attachment loss, or bone
loss, that affects only a single tooth should not be diag-
nosed as having periodontitis?
The requirement of “at least two affected teeth” has been
incorporated in the classification to minimize false positives,
that is, to preclude an inflation of periodontitis prevalence due
to incidental attachment loss. This restriction was also intro-
duced in recognition of the fact that “true” periodontitis sel-
dom affects only a single tooth in the dentition. However, if
according to the clinician’s judgment, an observed attachment
loss/bone loss lesion that affects a single tooth in an other-
wise intact dentition cannot be ascribed to a cause other than
periodontitis (e.g., root fracture, endodontic lesion, etc.), then
the clinician should bypass the rule, proceed with assigning a
diagnosis of periodontitis, stage it appropriately, and further
describe it as “localized.”
6 THE VALUE OF THE 2018
PERIODONTITIS CLASSIFICATION
Well-controlled longitudinal clinical studies of periodontitis
treatment have demonstrated that the standard principles for
control of periodontitis are remarkably successful in the long-
term control of the disease, but not for everyone. Over the
years, classification schemes have drawn attention to differ-
ent clinical phenotypes that may be expressed in some patients
with periodontitis. The 2018 periodontitis classification uses
the staging and grading system,1,3 as discussed above, to allow
clinicians to consistently (1) assess the current level of sever-
ity of periodontitis and its impact on the treatment required,
and (2) determine whether a periodontitis patient is highly
likely or less likely to respond predictably to standard princi-
ples for treating periodontitis. And perhaps most importantly,
the new classification guides a clinician to recognize factors
that indicate that the patient’s disease trajectory is more com-
plex and should be managed accordingly.
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